Cosmo Pharmaceuticals NV (XSWX:COPN) Share Price

Company Profile

Business description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.
Contact
Sir John Rogerson’s Quay
Riverside II
Dublin2
IRL
T: +353 18170370
E: [email protected]
https://www.cosmopharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
332

Recommended

Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.

Joseph Taylor | 11 September 2025

The media group has excelled in controlling what it can control. Now the focus shifts to capital deployment.

Brian Han | 11 September 2025

Shares jumped in response to the latest results.

Luke Yang, CFA | 11 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,128.70	18.10	0.20%
CAC 40	7,825.24	1.72	0.02%
DAX 40	23,698.15	5.50	-0.02%
Dow JONES (US)	45,834.22	273.78	-0.59%
FTSE 100	9,283.29	14.29	-0.15%
HKSE	26,388.16	301.84	1.16%
NASDAQ	22,141.10	98.03	0.44%
Nikkei 225	44,768.12	395.62	0.89%
NZX 50 Index	13,227.90	1.25	-0.01%
S&P 500	6,584.29	3.18	-0.05%
S&P/ASX 200	8,864.90	22.00	0.25%
SSE Composite Index	3,870.60	4.71	-0.12%